Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia [14]

Leukemia

Volumn 19, Issue 1, 2005, Pages 165-169

  Frost, Britt Marie ^a   Forestier, E ^b   Gustafsson, G ^c   Nygren, P ^d   Hellebostad, M ^e   Jonmundsson, G ^f   Kanerva, J ^g   Schmiegelow, K ^h   Larsson, R ^d   Lonnerholm G ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; AMSACRINE; ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CELL SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME BANDING PATTERN; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; KARYOTYPING; LETTER; LEUKEMIA CELL; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 19944426879     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403540     Document Type: Letter

References (12)

1. Rubnitz JE, Pui CH. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev 2003; 29: 31-44.
2. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996; 87: 1211-1224.
3. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1990; 76: 117-122.
4. Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998; 16: 527-535.
5. Pui CH, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J Clin Oncol 1994; 12: 2601-2606.
6. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
7. Chessells JM, Harrison G, Lilleyman JS, Bailey CC, Richards SM. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997; 98: 945-951.
8. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14 2267-2275.
9. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 376-385.
10. Forestier E, Johansson B, Gustafsson G, Borgstrom G, Kerndrup G, Johannsson J et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. Br J Haematol 2000; 110: 147-153.
11. Nygren P, Kristensen J, Jonsson B, Sundstrom C, Lonnerholm G, Kreuger A et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992; 6: 1121-1128.
12. Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood 2004; 104: 2452-2457.